| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
The insulin-like growth factor I receptor (IGF-IR) is involved in the control of breast cancer cell growth. The cytostatic activity of tamoxifen (Tam), a nonsteroidal antiestrogen, is partially mediated through interference with IGF-I-R-dependent proliferation, yet the effects of Tam on IGF-IR intracellular signaling have never been elucidated. Consequently, we investigated how Tam modifies the IGF-IR signaling pathway in estrogen receptor-positive MCF-7 breast cancer cells and in MCF-7-derived clones overexpressing either the IGF-IR (MCF-7/IGF-IR cells) or its major substrate, IRS-1 (MCF-7/IRS-1 cells). MCF-7/IGF-IR and MCF-7/IRS-1 cells exhibit greatly reduced estrogen growth requirements but retain estrogen receptors and express sensitivity to antiestrogens comparable to that in the parental cells. In all tested cell lines, regardless of the amplification of IGF signaling, a 4-day treatment with 10 nM Tam produced a similar cytostatic effect. In MCF-7 and MCF-7/IGF-IR cells, growth inhibition by Tam was associated with the reduced tyrosine phosphorylation of the IGF-IR in the presence of IGF-I; however, the basal level of the IGF-IR remained unaffected. Moreover, Tam inhibited both basal and IGF-I-induced tyrosine phosphorylation of IRS-1, which was accompanied by down-regulation of IRS-1-associated phosphatidylinositol 3'-kinase activity and reduced IRS-1/growth factor receptor-bound protein 2 (GRB2) binding. In contrast, under the same treatment, tyrosine phosphorylation of Src-homology/collagen proteins (SHC; another substrate of the IGF-IR) and SHC/GRB2 binding were elevated. The protein levels of the IGF-IR and IRS-1 were not modified by Tam, whereas SHC protein expression was either not affected or moderately decreased by the treatment.
In summary, this work provides the first evidence that in MCF-7 cells, cytostatic effects of Tam are associated with the modulation of IGF-IR signaling, specifically with: (a) down-regulation of IGF-I-induced tyrosine phosphorylation of the IGF-IR; (b) inhibition of IRS-1/phosphatidylinositol 3'-kinase signaling; and (c) up-regulation of SHC tyrosine phosphorylation and increased SHC/GRB2 binding. It is hypothesized that dephosphorylation of IRS-1 could be a major contributing factor in Tam cytostatic activity.
1 This work was supported in part by Grant DK 48969 from the NIH (to E. S.). E. S. is a recipient of Career Development Award DAMD 17-96-1-6250 from the Department of the Army.
2 To whom requests for reprints should be addressed, at Kimmel Cancer Institute BLSB 606A, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107. Phone: (215) 503-4512; Fax: (215) 923-0249.
Received 3/ 7/97. Accepted 5/13/97.
This article has been cited by other articles:
![]() |
D. Sisci, C. Morelli, C. Garofalo, F. Romeo, L. Morabito, F. Casaburi, E. Middea, S. Cascio, E. Brunelli, S. Ando, et al. Expression of nuclear insulin receptor substrate 1 in breast cancer J. Clin. Pathol., June 1, 2007; 60(6): 633 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hiscox, L Morgan, T. Green, and R. I Nicholson Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Van Den Bossche, S. Van Belle, F. De Winter, A. Signore, and C. Van de Wiele Early Prediction of Endocrine Therapy Effect in Advanced Breast Cancer Patients Using 99mTc-Depreotide Scintigraphy J. Nucl. Med., January 1, 2006; 47(1): 6 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
L-A Martin, S Pancholi, C M W Chan, I Farmer, C Kimberley, M Dowsett, and S R D Johnston The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling Endocr. Relat. Cancer, December 1, 2005; 12(4): 1017 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Gee, J F Robertson, E Gutteridge, I O Ellis, S E Pinder, M Rubini, and R I Nicholson Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S99 - S111. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Ibrahim and D. Yee Insulin-Like Growth Factor-I and Breast Cancer Therapy Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White, and L. M. Shaw Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis Mol. Cell. Biol., November 15, 2004; 24(22): 9726 - 9735. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, E. Hui, T. Ip, and L. U. Thompson Dietary Flaxseed Enhances the Inhibitory Effect of Tamoxifen on the Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) in Nude Mice Clin. Cancer Res., November 15, 2004; 10(22): 7703 - 7711. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Garofalo, D. Sisci, and E. Surmacz Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells Clin. Cancer Res., October 1, 2004; 10(19): 6466 - 6475. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-F. Chen and M.-S. Wong Genistein Enhances Insulin-Like Growth Factor Signaling Pathway in Human Breast Cancer (MCF-7) Cells J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2351 - 2359. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Boyd Insulin and Cancer Integr Cancer Ther, December 1, 2003; 2(4): 315 - 329. [Abstract] [PDF] |
||||
![]() |
J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro Endocrinology, November 1, 2003; 144(11): 5105 - 5117. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu, X.-O. Shu, B. D. L. Li, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng Joint Effect of Insulin-like Growth Factors and Sex Steroids on Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1067 - 1073. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Martin and A. Stoica Insulin-Like Growth Factor-I and Estrogen Interactions in Breast Cancer J. Nutr., December 1, 2002; 132(12): 3799S - 3801. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bompard, C. Puech, C. Prebois, F. Vignon, and G. Freiss Protein-tyrosine Phosphatase PTPL1/FAP-1 Triggers Apoptosis in Human Breast Cancer Cells J. Biol. Chem., November 27, 2002; 277(49): 47861 - 47869. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Varma and S. E. Conrad Antiestrogen ICI 182,780 Decreases Proliferation of Insulin-like Growth Factor I (IGF-I)-treated MCF-7 Cells without Inhibiting IGF-I Signaling Cancer Res., July 15, 2002; 62(14): 3985 - 3991. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. NICHOLSON, I. R. HUTCHESON, M. E. HARPER, J. M. KNOWLDEN, D. BARROW, R. A. McCLELLAND, H. E. JONES, A. E. WAKELING, and J.M. W. GEE Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 104 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ko, G. R. Cardona, A. Henrion-Caude, and W. W. Chin Identification and Characterization of a Tissue-Specific Coactivator, GT198, That Interacts with the DNA-Binding Domains of Nuclear Receptors Mol. Cell. Biol., January 1, 2002; 22(1): 357 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartucci, C. Morelli, L. Mauro, S. Ando', and E. Surmacz Differential Insulin-like Growth Factor I Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells Cancer Res., September 1, 2001; 61(18): 6747 - 6754. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Shaw Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the {alpha}6{beta}4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion Mol. Cell. Biol., August 1, 2001; 21(15): 5082 - 5093. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oesterreich, P. Zhang, R. L. Guler, X. Sun, E. M. Curran, W. V. Welshons, C. K. Osborne, and A. V. Lee Re-expression of Estrogen Receptor {alpha} in Estrogen Receptor {alpha}-negative MCF-7 Cells Restores both Estrogen and Insulin-like Growth Factor-mediated Signaling and Growth Cancer Res., August 1, 2001; 61(15): 5771 - 5777. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Yu, R. G. Foster, and D. C. Dean Transcriptional Repression by Rb-E2F and Regulation of Anchorage-Independent Survival Mol. Cell. Biol., May 15, 2001; 21(10): 3325 - 3335. [Abstract] [Full Text] |
||||
![]() |
D. L. Hadsell, T. Alexeenko, Y. Klemintidis, D. Torres, and A. V. Lee Inability of Overexpressed des(1-3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules Endocrinology, April 1, 2001; 142(4): 1479 - 1488. [Abstract] [Full Text] |
||||
![]() |
A. Chiarenza, P. Lazarovici, L. Lempereur, G. Cantarella, A. Bianchi, and R. Bernardini Tamoxifen Inhibits Nerve Growth Factor-induced Proliferation of the Human Breast Cancerous Cell Line MCF-7 Cancer Res., April 1, 2001; 61(7): 3002 - 3008. [Abstract] [Full Text] |
||||
![]() |
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Molloy, F. E. B. May, and B. R. Westley Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line J. Biol. Chem., April 21, 2000; 275(17): 12565 - 12571. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brinkman, S. van der Flier, E. M. Kok, and L. C. J. Dorssers BCAR1, a Human Homologue of the Adapter Protein p130Cas, and Antiestrogen Resistance in Breast Cancer Cells J Natl Cancer Inst, January 19, 2000; 92(2): 112 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Burtscher, A. Compagni, G. M. Lamm, and G. Christofori An Insulin-like Growth Factor-mediated, Phosphatidylinositol 3' Kinase-independent Survival Signaling Pathway in {beta} Tumor Cells Cancer Res., August 1, 1999; 59(16): 3923 - 3926. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Rosen Serum Insulin-like Growth Factors and Insulin-like Growth Factor-binding Proteins: Clinical Implications Clin. Chem., August 1, 1999; 45(8): 1384 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Lee, J. G. Jackson, J. L. Gooch, S. G. Hilsenbeck, E. Coronado-Heinsohn, C. K. Osborne, and D. Yee Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo Mol. Endocrinol., May 1, 1999; 13(5): 787 - 796. [Abstract] [Full Text] |
||||
![]() |
Z.-D. Xu, L. Oey, S. Mohan, M. H. Kawachi, N.-S. Lee, J. J. Rossi, and Y. Fujita-Yamaguchi Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid in Vitro and in Prostate Cancer Cells Endocrinology, May 1, 1999; 140(5): 2134 - 2144. [Abstract] [Full Text] |
||||
![]() |
G. Freiss, C. Puech, and F. Vignon Extinction of Insulin-Like Growth Factor-I Mitogenic Signaling by Antiestrogen-Stimulated Fas-Associated Protein Tyrosine Phosphatase-1 in Human Breast Cancer Cells Mol. Endocrinol., April 1, 1998; 12(4): 568 - 579. [Abstract] [Full Text] |
||||
![]() |
A. Lai, B. Sarcevic, O. W. J. Prall, and R. L. Sutherland Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1 J. Biol. Chem., July 6, 2001; 276(28): 25823 - 25833. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |